Business Description
PDS Biotechnology Corp
NAICS : 325412
SIC : 2834
ISIN : US2798701098
Total Employee Number:
21Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.28 | |||||
Equity-to-Asset | -0.41 | |||||
Debt-to-Equity | -1.22 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 22.9 | |||||
3-Year EPS without NRI Growth Rate | 19.7 | |||||
3-Year FCF Growth Rate | 12.7 | |||||
3-Year Book Growth Rate | -51.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.82 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 13.97 | |||||
9-Day RSI | 14.75 | |||||
14-Day RSI | 18.13 | |||||
3-1 Month Momentum % | -32.93 | |||||
6-1 Month Momentum % | 20.55 | |||||
12-1 Month Momentum % | -35.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.57 | |||||
Quick Ratio | 0.57 | |||||
Cash Ratio | 0.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.1 | |||||
Shareholder Yield % | 8.72 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -481.32 | |||||
ROA % | -121 | |||||
ROIC % | -279.15 | |||||
3-Year ROIIC % | 198.51 | |||||
ROC (Joel Greenblatt) % | -11080.39 | |||||
ROCE % | -164.16 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.41 | |||||
EV-to-Forward-EBIT | -0.39 | |||||
EV-to-EBITDA | -0.41 | |||||
EV-to-Forward-EBITDA | -0.39 | |||||
EV-to-Forward-Revenue | 47.25 | |||||
EV-to-FCF | -0.66 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -137.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PDS Biotechnology Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.55 | ||
| Beta | 1.9981 | ||
| 3-Year Sharpe Ratio | -0.82 | ||
| 3-Year Sortino Ratio | -1.13 | ||
| Volatility % | 86.53 | ||
| 14-Day RSI | 18.13 | ||
| 14-Day ATR (€) | 0.045371 | ||
| 20-Day SMA (€) | 0.4214 | ||
| 12-1 Month Momentum % | -35.29 | ||
| 52-Week Range (€) | 0.168 - 1.225 | ||
| Shares Outstanding (Mil) | 55.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PDS Biotechnology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PDS Biotechnology Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 08:00 | In 82 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 81 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | 0.21 (-5.45%) | ||
| General meeting for 2026 | 2026-08-10 08:00 | 0.65 (+1.57%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 08:00 | 1.10 (+0.46%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 1.10 (+0.46%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 08:00 | 0.49 (-8.97%) | ||
| Annual report for 2025 | 2026-03-30 | 0.49 (-8.97%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 0.49 (-8.97%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 08:00 | 0.84 (-4.27%) |
Show
Entries
PDS Biotechnology Corp Frequently Asked Questions
What is PDS Biotechnology Corp(STU:EU6)'s stock price today?
The current price of STU:EU6 is €0.18. The 52 week high of STU:EU6 is €1.23 and 52 week low is €0.17.
When is next earnings date of PDS Biotechnology Corp(STU:EU6)?
The next earnings date of PDS Biotechnology Corp(STU:EU6) is 2026-11-13 Est..
Does PDS Biotechnology Corp(STU:EU6) pay dividends? If so, how much?
PDS Biotechnology Corp(STU:EU6) does not pay dividend.
Press Release
Articles on PDS Biotechnology Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers